Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes

Publisher： Karger

E-ISSN： 1423-0232|93|2|127-135

ISSN： 0030-2414

Source： Oncology, Vol.93, Iss.2, 2017-05, pp. : 127-135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inflammation-Based Prognostic Score Predicts Survival in Patients with Advanced Gastric Cancer Receiving Biweekly Docetaxel and S-1 Combination Chemotherapy

By  

Oncology, Vol. 83, Iss. 4, 2012-08 ,pp. : 183-191

Karger

Access to resources Recommend Favorite

A Phase II Study of Epirubicin, Cisplatin and Capecitabine Combination Chemotherapy in Patients with Metastatic or Advanced Gastric Cancer

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 333-340

Karger

Access to resources Recommend Favorite

Impact of S-1 plus Cisplatin Neoadjuvant Chemotherapy on Scirrhous Gastric Cancer

By  

Oncology, Vol. 88, Iss. 5, 2015-01 ,pp. : 281-288

Karger

Access to resources Recommend Favorite

Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer

By  

Oncology, Vol. 73, Iss. 1-2, 2008-03 ,pp. : 2-8

Karger

Access to resources Recommend Favorite

Combination of Trastuzumab and Triple FLOT Chemotherapy (5-Fluorouracil/Leucovorin, Oxaliplatin, and Docetaxel) in Patients with HER2-Positive Metastatic Gastric Cancer: Report of 3 Cases

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 505-508

Karger

Access to resources Recommend Favorite